Clinical Study of Telmisartan in the Treatment of Hypertension

Objective To investigate the clinical safety and efficacy of telmisartan in the treatment of patients with mild to moderate hypertension. Methods One hundred thirty-nine patients with mild to moderate hypertension were randomly divided into telmisartan ( n =72, 40-80 mg/d) or fosinopril( n =67, 10-20 mg/d) for 26 weeks. Ambulatory blood pressure monitoring was undertaken before and after the treatment. 24 hours mean blood pressure, trough/peak ratio, BP in 2:00-{8:00} AM, effective rate, and side effects were evaluated. Results Both SBP and DBP decreased in two groups after the treatment. The effective rates were 75% in telmisartan group and 72% in fosinopril group. The trough/peak ratio in telmisartan group was higher than that in fosinopril group (SBP 72% vs 62%, DBP 75% vs 63%). Reduction of mean SBP and DBP in telmisartan group was greater than that in fosinopril group during 2:00-8:00 AM period. Telmisartan was well tolerated. ConclusionTelmisartan is safe and effective in the treatment of mild to moderate hypertension.